ð¶ãæ°è¬ã¡ãŒã«ãŒãã¡ãã£ã«ã«ã¢ãã§ã¢ãŒãºè·ïŒæ±äº¬ã»å€§éªïŒ
800~1000äž
äŒæ¥åéå ¬é
æ±äº¬éœäžå€®åº, 倧éªåºå€§éªåž
800~1000äž
äŒæ¥åéå ¬é
æ±äº¬éœäžå€®åº, 倧éªåºå€§éªåž
å»è¬åã¡ãã£ã«ã«ãµã€ãšã³ã¹ãªãšãŸã³
ãã®ä»å»è¬ååŠè¡/ã¡ãã£ã«ã«ã¢ãã§ã¢ãŒãº
å»è¬åã¡ãã£ã«ã«ã¢ãã§ã¢ãŒãº
ãäž»ãªæ¥åå 容ã å»è¬åãåçå»çç補åããã³éçºåã«é¢ããã¡ãã£ã«ã«ã¢ãã§ã¢ãŒãºæ¥å ã»å»ççŸå Žãšã®å¯Ÿè©±ãéããã¢ã³ã¡ããã¡ãã£ã«ã«ããŒãºã®ææ¡ ã»ã¡ãã£ã«ã«ãã©ã³ã®ç«æ¡ããã³çå® ã»èšåºç ç©¶ã»ãªã¢ã«ã¯ãŒã«ãããŒã¿ç ç©¶çã®äŒç»ã»ç«æ¡ã»æšé² ã»æ°èŠãšããã³ã¹åµåºæŠç¥ã®çå®ãšå®è¡ ã»å¯Ÿè±¡çŸæ£ããã³è£œåã®é©æ£äœ¿çšã«é¢ããåŠè¡æŽ»åãçŸæ£åçºæŽ»å ã»è«æäœæãåŠäŒçºè¡šããã³åŠè¡æ å ±çºä¿¡ ã»Key Thought LeaderïŒKTLïŒãšã®ç§åŠçãã£ã¹ã«ãã·ã§ã³ãéããé¢ä¿æ§ç¯ ã»åœå å€ã®ã¡ãã£ã«ã«ãç ç©¶éçºãäºæ¥éšéãšã®ã¯ãã¹ãã¡ã³ã¯ã·ã§ãã«ãªåå ã»éçºåææ®µéããã®ã¡ãã£ã«ã«ã€ã³ãµã€ãåéãéçºæŠç¥ãžã®æèš ãä»äºã®é åã»ãã£ãªã¢ãã¹ã ã¡ãã£ã«ã«ã¢ãã§ã¢ãŒãºéšã¯ãç ç©¶ãéçºãå¶æ¥ãªã©å€æ§ãªããã¯ã°ã©ãŠã³ããæã€ã¡ã³ããŒã§æ§æãããŠããŸããåèªã®åŒ·ã¿ãå°éæ§ãå°éããªããåžè²©åããéçºåãåçå»çç補åãŸã§å¹ åºãããŒããã©ãªãªãæ åœããå»çããŒãºã®ææ¡ãããšããã³ã¹åµåºãçºä¿¡ã»æ®åãŸã§äžè²«ããŠæºããããšãã§ããŸããã°ããŒãã«ãããžã§ã¯ããžã®åç»ãçµç¹ãããžã¡ã³ããªã©å€æ§ãªãã£ãªã¢åœ¢æãå¯èœã§ãã ãŸããåé åã§ã¯èªãäŒç»ãå®è¡ããæ©äŒã«æµãŸããŠããŸããç¹ã«ããŒã¿åµçãäžå¿ã«å€æ§ãªç ç©¶èœåãæãããµã€ãšã³ã¹ãåºç€ãšããªããã以äžéšéã®ããžã§ã³ã»ããã·ã§ã³ãå ±éã®æ³ããšããŠã¡ã³ããŒã掻èºããŠããŸãã
ã»è£œè¬äŒæ¥ã«ãããMA/MSLæ¥åçµéšïŒ3幎以äžïŒ ã»å»çåŸäºè ãšã®ç§åŠçãã£ã¹ã«ãã·ã§ã³çµéš ã»èšåºç ç©¶ã®äŒç»ãç«æ¡ãæšé²çµéš ã»è«æäœæãŸãã¯åŠäŒçºè¡šçµéš
倧åŠé¢ïŒä¿®å£«ïŒã倧åŠé¢ïŒå士ïŒ
æ£ç€Ÿå¡
ç¡
æ è©Šçšæéææ°: 3ã¶æ
800äžåã1,000äžå
å šé¡æ¯çµŠ
120æ¥ å èš³ïŒå®å šé±äŒ2æ¥å¶ãåæ æ¥æ ç¥æ¥
å¥åº·ä¿éº åç幎é éçšä¿éº åŽçœä¿éº
â»äžèšã¯ãããŸã§ãæ³å®å¹Žåã«ãªããŸãã
ç¡
æ±äº¬éœäžå€®åº
倧éªåºå€§éªåž
åšå® å€å ãªã¢ãŒãã¯ãŒã¯å¯
æ
æ
瀟å¡é£å ãã«ãã§ããªã¢ãã©ã³ã財圢貯èå¶åºŠãåŸæ¥å¡ææ ªäŒãå ±æžäŒãè»¢å€æç€Ÿå® å¶åºŠ
1å
ã2å
æ¥ç³»è£œè¬ã¡ãŒã«ãŒ
æçµæŽæ°æ¥ïŒÂ
600~700äž
ãäŒç€Ÿã»ããžã·ã§ã³ã®é åã â EPSã°ã«ãŒãã®å®å®åºç€ãšé«ãå°éæ§ åœç€Ÿã¯EPSã°ã«ãŒãã®äžå¡ãšããŠãå»è¬åã»å»çæ©åšæ¥çã«ç¹åããBPOã»DIãµãŒãã¹ãå±éããŠããŸãã補è¬äŒæ¥ã®è¬æŒäŒã§äœ¿çšãããçºè¡šçšã¹ã©ã€ãããã³ã³ãã©ã€ã¢ã³ã¹æ³èŠãèªäž»èŠç¯ã«åºã¥ã審æ»ãããã¹ã©ã€ãã¬ãã¥ãŒéšéãã¯ãæ¥ççµéšè ãå»çç³»æè³æ Œè ã倿°åšç±ãããã®é«ãå質ããã¯ã©ã€ã¢ã³ããã絶倧ãªä¿¡é ŒãåŸãŠããŸãã â è£éããç°å¢ãšæç¢ºãªãã£ãªã¢ãã¹ æšä»ã®ã³ã³ãã©ã€ã¢ã³ã¹æèã®é«ãŸããåããåœéšéã®ããŒãºã¯å¹Žã æ¡å€§ããŠããŸããããªãã«ã¯ã°ã«ãŒããããŒãžã£ãŒãšããŠãæ¢åãµãŒãã¹ã®æ¡å€§ãæ¥åå¹çåãæ°èŠããžãã¹ã®äŒç»ãªã©ãéšéã®ãããªãæé·ãçœåŒããŠããã ããŸããå°æ¥çã«ã¯ãã¡ãã£ã«ã«ã¢ãã§ã¢ãŒãºéšå šäœãçµ±æ¬ãããããŒãžã£ãŒè·ãç®æãããããããã®ããããžã·ã§ã³ã§ãã â ã転å€ãªããã§å¶ããã¯ãŒã¯ã©ã€ããã©ã³ã¹ å€åå°ã¯æ±äº¬ã»æ± è¢ã転å€ã¯ãããŸãããå®å šé±äŒ2æ¥å¶ïŒåæ¥ç¥ïŒã幎éäŒæ¥120æ¥ä»¥äžã§ããã¬ãã·ãã«äŒæãæéåäœã§ã®æäŒååŸãªã©ãæè»ãªåãæ¹ãå¯èœãªç°å¢ãæŽã£ãŠããŸãã ãæ¥åå 容ã 補è¬äŒæ¥ãã¯ã©ã€ã¢ã³ããšãããè¬æŒäŒæŒè çºè¡šçšã¹ã©ã€ãäºåã¬ãã¥ãŒãµãŒãã¹ãéšéã«ãŠãã°ã«ãŒããããŒãžã£ãŒãšããŠä»¥äžã®æ¥åããä»»ãããŸãã ã»ã¡ã³ããŒã®è²æãç®æšç®¡çãè©äŸ¡ ã»ã¹ã©ã€ãã¬ãã¥ãŒæ¥åã®ãããžã¡ã³ãïŒé²è¡ç®¡çãéå¶ãå質管çïŒ ã»æ¥åæ¹åãæšæºåã®æšé²ïŒAIãããžã¿ã«ããŒã«ã®å°å ¥æ€èšãªã©ïŒ ã»ç€Ÿå åé¢ä¿éšçœ²ãšã®é£æºãèª¿æŽ ã»ã¯ã©ã€ã¢ã³ããšã®æè¡ã亀æžã課é¡è§£æ±ºå¯Ÿå¿
ãæ±ããèŠä»¶ã ïŒå¿ é èŠä»¶ïŒ ã»è£œè¬äŒæ¥ã§ã®ãããžã¡ã³ã(管çè·)çµéš ã»è£œè¬æ¥çã«ãããã³ã³ãã©ã€ã¢ã³ã¹é¢é£æ³èŠãèªäž»èŠç¯ã«é¢ããæ·±ãç¥èãšçè§£ ã»æ¥åæ¹åãæšæºåãæšé²ããå質åäžã«åãçµãã ãçµéš ã»ã¡ã³ããŒã®è²æãæå°ãè©äŸ¡ãã§ãããªãŒããŒã·ãã ã»ã¯ã©ã€ã¢ã³ããšã®æè¡ã課é¡è§£æ±ºãæšé²ã§ããã³ãã¥ãã±ãŒã·ã§ã³ã¹ãã« ã»åºæ¬çãªPCã¹ãã«ïŒMicrosoft Officeå šè¬ïŒ ïŒæè¿èŠä»¶ïŒ ã»ã¹ã©ã€ãã¬ãã¥ãŒæ¥åããŸãã¯é¢é£æ¥åã«ãããå®åçµéš ã»AIã¬ãã¥ãŒãããžã¿ã«ããŒã«å°å ¥ãªã©ã®æ¥åæ¹é©ãDXæšé²ã®çµéš
EPãã¡ãŒãã©ã€ã³ã¯ãEPSã°ã«ãŒãã®äžå¡ãšããŠãå»è¬åã»å»çã»å»çæ©åšã»ãã«ã¹ã±ã¢æ¥çã«ç¹åãããDIãµãŒãã¹ -ã³ã³ã¿ã¯ãã»ã³ã¿ãŒãµãŒãã¹-ããBPOãµãŒãã¹ããå»çæ©åšãµããŒããµãŒãã¹ãããã«ããã£ãã«ããã¢ãŒã·ã§ã³ãµãŒãã¹ãããã«ã¹ã±ã¢ãµããŒããµãŒãã¹ãã®5ã€ã®åºè»žãµãŒãã¹ã«ãããŠã åžžã«ã客æ§ã®ããŒãºã«ãå¿ãã§ãããœãªã¥ãŒã·ã§ã³ãéçºã»æäŸããŠããŸãã
500~800äž
ç é¢çµå¶ã®æ¹åãç®çãšããã³ã³ãµã«ãã£ã³ã°ãããžã§ã¯ãã«ãããŠãããŒã¿åæã軞ãšããã³ã³ãµã«ã¿ã³ãã®æ¯æŽæ¥åãæ åœããŸãããŸãã¯ã¢ããªã¹ããšããŠãç é¢ã®çµå¶ææšã蚺çå®çžŸãªã©ããã³ãããŒã¯ããŒã¿ãšæ¯èŒã»åæãã課é¡ãæ¹åäœå°ãæŽçããŸãããã®åæçµæãããšã«ãçµå¶å±€ãžã®ææ¡è³æããã¬ãŒã³ããŒã·ã§ã³è³æãäœæããç é¢çµå¶æ¹åã«åããæææ±ºå®ããµããŒãããŸãã çµéšãç©ãã åŸã¯ãç é¢çµå¶ã³ã³ãµã«ã¿ã³ããšããŠå»çæ©é¢ãžã®ææ¡ã»æ¹åæ¯æŽãŸã§æ åœç¯å²ãåºããå»çã®è³ªåäžãšçµå¶å¹çåãäž¡ç«ãããããã®ã³ã³ãµã«ãã£ã³ã°ã宿œããŸããå瀟ã匷ã¿ãšãããã³ãããŒã¯ææ³ã掻çšããå»çæ©é¢ããšã®èª²é¡ãå¯èŠåããªãããæç¶å¯èœãªç é¢çµå¶ã®å®çŸãæ¯æŽããããžã·ã§ã³ã§ãã
å¿ é èŠé ã»å幎å¶å€§åŠåæ¥ä»¥äžã®åŠæŽãæããæ¹ ã»å»çæ©é¢ïŒå»åž«ãçè·åž«ãè¬å€åž«ãèšåºæ€æ»æåž«ãèšºçæ å ±ç®¡ç士ãå»çäºåãªã©ïŒãŸãã¯è£œè¬äŒæ¥ãå»çæ©åšã»å»çææã¡ãŒã«ãŒãªã©å»çé¢é£äŒæ¥ã§ã®å®åçµéš ã»å»çå¶åºŠãç é¢çµå¶ãè¬å€ãå»çææãªã©ãããããã®å°éé åã«ãããŠåŒ·ã¿ãšãªãç¥èã»çµéš ã»çŸè·ãŸãã¯åè·ã§é«ãè©äŸ¡ãåããå®çžŸ ã»ExcelãWordãPowerPointãçšããè³æäœæã»åæã¹ãã« ã»æ°å€ããŒã¿ãããšã«èª²é¡ãæŽçããåæã§ããèœåïŒDPCããŒã¿çã®ç¥èŠãå«ãïŒ æè¿èŠé ã»ç é¢çµå¶æ¹åãå»ççµå¶ã«é¢ããç¥èã»çµéš ã»çµå¶ããŒã¿ã®åæããã³ãããŒã¯åæã®çµéš ã»ãã¬ãŒã³ããŒã·ã§ã³è³æã®äœæçµéš ã»ã³ã³ãµã«ãã£ã³ã°æ¥åãžã®åŒ·ãèå³ã»å¿å â»ã³ã³ãµã«ãã£ã³ã°æªçµéšè ã®å¿åãå¯èœã§ãã
-
700~1100äž
ãåœç€Ÿç޹ä»ã æšä»ã®å»çãåãå·»ãç°å¢ããåžæ°ã®æèã®å€åãåãæ¢ããŠããæ£è ã»å®¶æãèªå·±ç®¡çããããããŒã«ãå»çè ãåŸæŒãããããšã§ãæ£è ã®æ²»çãéçåäºé²ã®äžå©ã«å°ãã§ããªãã°ãšã®æãã§ã¹ã¿ãŒãããŸããã PHR ïŒPersonal Health RecordïŒ åéã®ã¢ããªãå»çé¢ä¿è ãå»çæ¥çãåãå·»ããã¬ãŒã€ãŒïŒè£œè¬/å»çæ©åšã¡ãŒã«ãŒãèªæ²»äœïŒãšå ±ã«å ±åã§ãµãŒãã¹ã®éçºãéå¶ãããŠããŸãã PHR ãšã¯æ£è ãèªåèªèº«ã®å»çã»å¥åº·æ å ±ã®èšé²ãã¢ããªå ã§ã®å»çåŸäºè ãšã®ã³ãã¥ãã±ãŒã·ã§ã³ãéããŠãæ²»çããµããŒããããµãŒãã¹ã§ãã倿°ã®çŸæ£é åãšæŽ»çšç®çã§çŽ40Projectè¶ ã®å®çžŸãæã£ãŠããŸãããŸããPHRã«é¢ãããµãŒãã¹äºæ¥è ã«ãã©ãããã©ãŒã æäŸãããããšãããã®æ£è ãããã¯ãŒã¯ãéãããããŒã±ãã調æ»ãèšåºç ç©¶ã®è¢«éšè ãªã¯ã«ãŒãã£ã³ã°ãªã©ã®å¿âœ€äºæ¥ãå±éããŠããŸãã ãåéèæ¯ã è¶ é«éœ¢ç€ŸäŒãè¿ã瀟äŒä¿é財æ¿ãã²ã£è¿«ããæ¥æ¬ã«ãããŠãçŸæ£åçºã»å蚺å§å¥šã®éèŠæ§ãå¢ããšãšãã«çŸæ£ã®æ²»çæ¯æŽãéçåäºé²ããããŠäºåŸã»QOLåäžã®èгç¹ããã補è¬äŒæ¥ã®ã¿ãªããä¿éºäŒç€Ÿãæ§ã ãªäŒæ¥ãä»åŸã®åå¥åå»çãæ£è äžå¿å»çã«åããæ£è ã»ç掻è åãã®æ°ããªããžã¿ã«ãã«ã¹æŠç¥ãéèŠèŠããŠãããPHRãµãŒãã¹ã®å¿ èŠæ§ãäºæ¥ããã³ã·ã£ã«ãé«ããªã£ãŠããã ãã®ãããªç¶æ³äžãB2Bäºæ¥æé·ãã¡ãã£ã«ã«èŠç¹ã§ãªãŒããã補è¬äŒæ¥ãäžå¿ãšããèšåºç ç©¶ã»æ²»éšã«ãããPHR掻çšãäŒç»ã»ææ¡ã»æšé²ã§ããã¡ãã£ã«ã«ãšãã¹ããŒããå¢åŒ·ããããšãæ€èšããŠããŸãã ãæ¥åæŠèŠã B2Bäºæ¥æé·ãã¡ãã£ã«ã«èŠç¹ã§ãªãŒãã»æ¯æŽãã補è¬äŒæ¥ãäžå¿ãšããèšåºç ç©¶ã»æ²»éšã«ãããPHRãPHRããŒã¿æŽ»çšã«ã€ããŠäŒç»ã»ææ¡ã»æšé²ãããå ããŠã瀟å é¢é£ã¡ã³ããŒã忥ããŒãããŒãšã®é£æºãéããŠèšåºç ç©¶ã»æ²»éšãããžã§ã¯ãããªãŒãã»æ¯æŽããããã詊éšã®æåã«å¯äžããããŸãã詊éšçµæãã广çãªãšããã³ã¹ã®åµåºã«ç¹ãããšãšãã«ãåŠäŒã»ã€ãã³ãçãžã®åºå±ã»ç»å£çã®ç§åŠç掻åãéããPHRæ®åã«ãè²¢ç®ããã â ä»äºå 容 ã»è£œè¬äŒæ¥ãäžå¿ãšããB2Bäºæ¥ã«ãããã¡ãã£ã«ã«æŠç¥ã»èšç»ãç«æ¡ã»æšé²ã»æ¯æŽ ã»äž»èŠãªè£œè¬é¡§å®¢ã«ãããæ°èŠæ¡ä»¶åµåºã®æ¯æŽã課é¡è§£æ±º ãš äžäœè·ãšã®é¢ä¿åŒ·åã»æ§ç¯ ã»äž»èŠã¢ã©ã€ã¢ã³ã¹ããŒãããŒãšã®åæ»ãªé£æºã»ã³ã©ãã¬ãŒã·ã§ã³ã»é¢ä¿åŒ·å ã»éšå çµç¹ã®æé·ã»åŒ·åã«ç¹ããæå±éšå¡ã®æ¯æŽ ã»ç€Ÿå é¢é£éšçœ²ã»çµå¶ã¡ã³ããŒãšã®åæ»ãªé£æºã»ã³ã©ãã¬ãŒã·ã§ã³ ãæ¬ããžã·ã§ã³ã®éèŠæ§ã åœç€Ÿäž»èŠäºæ¥ã§ãã補è¬äŒæ¥ãäžå¿ãšããB2Bäºæ¥ã®æé·ãšå®éã»å®æ§ç®æšéæã«åããã¡ãã£ã«ã«èŠç¹ã®äŒç»ã»ææ¡ã»æšé²ã»æ¯æŽãšããããã·ã§ã³ãæ ãããèšåºç ç©¶ã»æ²»éšã«é¢ãã顧客ãã¢ã©ã€ã¢ã³ã¹ããŒãããŒãšã®èª¿æŽã»äº€æžã»é£æºã»é¢ä¿åŒ·åã«å¯ŸããŠã¯ãã¡ãã£ã«ã«ãšãã¹ããŒããšããŠäž»äœçã»èœåçãã€äžå¿çã«æŽ»åé ããå ããŠãéšçœ²ã¡ã³ããŒã®æ¯æŽãé¢é£éšçœ²ãšã®å調ã«ããäŒç€Ÿç®æšã®éæã«å¯äžããã ãããžã·ã§ã³ã ãããããïŒèº«ã«çããããã¹ãã«ã âãããã æ¥æ¬ãæ±ããå»çã»ãã«ã¹ã±ã¢é åã®ç€ŸäŒèª²é¡è§£æ±ºãžã®è²¢ç®ãæ£è äžå¿å»çã®å®çŸãžã®è²¢ç®ãPHRãµãŒãã¹ãããžã¿ã«æè¡ãé§äœ¿ããŠãªãŒãã»äœæã§ããããããŠãèªèº«ã®ä»äºãçµå¶ã«ç¹ããçµæãšããŠèŠããããšãäžå ŽäŒæ¥ã®çµå¶ããŠããŠãææ°ã®ããžã¿ã«ãã«ã¹æŠç¥ãäœæã»å®è·µã§ããã â身ã«çããããã¹ãã«ã»ç¥è ã»å»çãã«ã¹ã±ã¢é åã«ãããB2Bäºæ¥ã¹ãã«ã»ç¥èã»ãã£ãªã¢ãç©ãããšãåºæ¥ãã ã»ITã»ããžã¿ã«è»žã§å»çãå»è¬ãæ²»çãæ£è ãµããŒããªã©ã®ç€ŸäŒè²¢ç®ãåºæ¥ãã ã»ãã³ãã£ãŒæ°è³ªã®é«ãçµç¹ã«ãŠã¢ã©ã€ã¢ã³ã¹é£æºçãéããäºæ¥äŒç»ã»æšé²ã«é¢ããããŠããŠã»çµéšãååŸããããšãã§ããã âåãããã ã»ååãé±4æ¥ãªãã£ã¹åºå€ãšãªã¢ãŒãå€åã®ãã€ããªããå€åãåæã«èªèº«ã®åãæ¹ãå®è·µã§ããã ã»çµå¶ã¡ã³ããŒãšã®å¯ãªé£æºã»åè°ã»ãã£ã¹ã«ãã·ã§ã³ãã§ããçµå¶ãšã®äžäœæãããã ã»éšçœ²å ã«ãããŠã¯ãå°äººæ°ã»ãã©ãããªçµç¹ã«ããå調ãäŒè©±ã«ããå¿ççå®å šæ§ãããã
â å¿åè³æ ŒïŒå¿ é ïŒ ã»è£œè¬ã»å»çæ©åšäŒæ¥ã§ã®ã¡ãã£ã«ã«ã¢ãã§ã¢ãŒãºéšéãèšåºéçºéšéã®çµéš5幎以äžããæ¹ or ã»è£œè¬äŒæ¥åãã³ã³ãµã«ãã£ã³ã°æ¥åãšããŠèšåºç ç©¶ã»æ²»éšãã¶ã€ã³ã»äŒç»çµéš5幎以äžããæ¹ ã»æ²»éšãå«ãèšåºç ç©¶ãã¬ãžã¹ããªãŒç ç©¶ãåžè²©åŸèª¿æ»ãããŒã¿ããŒã¹ç ç©¶ãªã©ã®ç ç©¶ãã¶ã€ã³ã«é¢ããé©åãªè°è«ãã§ããæ¹ ã»è£œè¬ã»å»çæ©åšäŒæ¥ã®ã¡ãã£ã«ã«ã¢ãã§ã¢ãŒãºãéçºãCROãªã©ã®ã¹ããŒã¯ãã«ããŒãšè°è«ãããªããç ç©¶ãã¶ã€ã³ã®è°è«ãå«ãç ç©¶æšé²ãã§ããæ¹ ã»ããžãã¹è±äŒè©±ãã§ããããšïŒå€è³ç³»äŒæ¥ãšã®æè¡ãããããïŒ â å¿åè³æ ŒïŒæè¿ïŒ ã»ããžã¿ã«ãã«ã¹ããŒã«ãçšããçµéšãããæ¹ ã»è±èªãçšããŠã°ããŒãã«æ¬ç€Ÿãšã®ç ç©¶ã«é¢ããè°è«ãã§ããæ¹ ã»è£œè¬ã»å»çæ©åšäŒæ¥ãå»çæ¥çã«ãããè±å¯ãªå°éç¥èãšå¹ åºããããã¯ãŒã¯ããæã¡ã®æ¹ â æ±ãã人ç©å ã»èªéšçœ²ã ãã§ã¯ãªããäŒç€Ÿå šäœã®ããšãèãèšåã»è¡åã§ããæ¹ ã»æŠç¥ã»èšç»ã»ç®æšçå®ãšãã®éæææ³ãããžã«ã«ã«èšèšã»å®è¡ã»ãªãŒãã§ããå ã»ä»è²¬ã«ãã責任æããæã¡ã®æ¹ ã»ãããžã§ã¯ãããªãŒãããåãããŒã ãçºããåãåèª¿ã»æ¯æŽåã®ããæ¹ ã»æ·±ãB2Bã³ãã¥ãã±ãŒã·ã§ã³ã¹ãã«ã»ææ¡åãšèª¿æŽèœåã®ããæ¹ ã»ç®æšããããžã§ã¯ãéæã«åãæãã®ããæ¹
ã¢ããªãwebãµãŒãã¹ãããŒã¿ãããžã¡ã³ããéããŠãæ£è ãããæé©ãªå»çãåŸãããã®æå©ããšãªããããžã¿ã«ãã«ã¹ãœãªã¥ãŒã·ã§ã³ãæäŸããŠããäŒæ¥ çæŽ»ç¿æ £ç ãããã®ä»å€çš®å€æ§ãªçäŸã«åãããŠãæ£è ããã®ãèªå·±ç®¡çãããµããŒããããµãŒãã¹ãããŒã«ã®éçºã»éå¶äºæ¥ãè¡ã£ãŠããŸãã æŽã«ã¯ãå»çæ¥çãåãå·»ããã¬ãŒã€ãŒïŒè£œè¬äŒæ¥ãå»çæ©åšã¡ãŒã«ãŒãå»çé¢ä¿è ãå°æ¹èªæ²»äœçïŒã«å¯ŸããããŒã±ãã£ã³ã°ãããã¢ãŒã·ã§ã³æ¯æŽã調æ»ã»åæäºæ¥ãªã©ãè¡ã£ãŠããŸãã
700~1500äž
ããã¢ãŒã·ã§ã³ãæè²ãåºçãªã©ç€Ÿå å€ã§äœ¿çšãããã¡ãã£ã«ã«ã³ãã¥ãã±ãŒã·ã§ã³ã®ã³ã³ãã©ã€ã¢ã³ã¹ã¬ãã¥ãŒetc
ããã¢ãŒã·ã§ã³ãæè²ãåºçãªã©ç€Ÿå å€ã§äœ¿çšãããã¡ãã£ã«ã«ã³ãã¥ãã±ãŒã·ã§ã³ã®ã³ã³ãã©ã€ã¢ã³ã¹ã¬ãã¥ãŒããªãŒãããçµéš ã°ããŒãã«/ããŒã«ã«ããªã·ãŒãæé ãã¬ã€ãã©ã€ã³ãèŠå¶ãæ·±ãçè§£ããå»çæ å ±åãåããã«å¯Ÿå¿ããæ©èœã管çããçµéš
-
600~1000äž
ãäž»ãªæ¥åå 容ã å»è¬åãåçå»çç補åããã³éçºåã«é¢ããã¡ãã£ã«ã«ã¢ãã§ã¢ãŒãºæ¥å ã»å»ççŸå Žãšã®å¯Ÿè©±ãéããã¢ã³ã¡ããã¡ãã£ã«ã«ããŒãºã®ææ¡ ã»ã¡ãã£ã«ã«ãã©ã³ã®ç«æ¡ããã³çå® ã»èšåºç ç©¶ã»ãªã¢ã«ã¯ãŒã«ãããŒã¿ç ç©¶çã®äŒç»ã»ç«æ¡ã»æšé² ã»æ°èŠãšããã³ã¹åµåºæŠç¥ã®çå®ãšå®è¡ ã»å¯Ÿè±¡çŸæ£ããã³è£œåã®é©æ£äœ¿çšã«é¢ããåŠè¡æŽ»åãçŸæ£åçºæŽ»å ã»è«æäœæãåŠäŒçºè¡šããã³åŠè¡æ å ±çºä¿¡ ã»Key Thought LeaderïŒKTLïŒãšã®ç§åŠçãã£ã¹ã«ãã·ã§ã³ãéããé¢ä¿æ§ç¯ ã»åœå å€ã®ã¡ãã£ã«ã«ãç ç©¶éçºãäºæ¥éšéãšã®ã¯ãã¹ãã¡ã³ã¯ã·ã§ãã«ãªåå ã»éçºåææ®µéããã®ã¡ãã£ã«ã«ã€ã³ãµã€ãåéãéçºæŠç¥ãžã®æèš ãä»äºã®é åã»ãã£ãªã¢ãã¹ã ã¡ãã£ã«ã«ã¢ãã§ã¢ãŒãºéšã¯ãç ç©¶ãéçºãå¶æ¥ãªã©å€æ§ãªããã¯ã°ã©ãŠã³ããæã€ã¡ã³ããŒã§æ§æãããŠããŸããåèªã®åŒ·ã¿ãå°éæ§ãå°éããªããåžè²©åããéçºåãåçå»çç補åãŸã§å¹ åºãããŒããã©ãªãªãæ åœããå»çããŒãºã®ææ¡ãããšããã³ã¹åµåºãçºä¿¡ã»æ®åãŸã§äžè²«ããŠæºããããšãã§ããŸããã°ããŒãã«ãããžã§ã¯ããžã®åç»ãçµç¹ãããžã¡ã³ããªã©å€æ§ãªãã£ãªã¢åœ¢æãå¯èœã§ãã ãŸããåé åã§ã¯èªãäŒç»ãå®è¡ããæ©äŒã«æµãŸããŠããŸããç¹ã«ããŒã¿åµçãäžå¿ã«å€æ§ãªç ç©¶èœåãæãããµã€ãšã³ã¹ãåºç€ãšããªããã以äžéšéã®ããžã§ã³ã»ããã·ã§ã³ãå ±éã®æ³ããšããŠã¡ã³ããŒã掻èºããŠããŸãã ãVisionã ã¢ã³ã¡ããã¡ãã£ã«ã«ããŒãºãæºããããšã«ãããInnovation today, healthier tomorrowsã®å®çŸã«è²¢ç®ãã ãMissionã å»çããŒãºã«å¿ããé«è³ªãªãšããã³ã¹åµåºã»çºä¿¡ã»æ å ±æäŸãè¡ããæ£è çãäžå¿ãšãã瀟äŒããã³å»çé¢ä¿è ã«ãšã£ãŠã®èªç€Ÿå»è¬åçã®äŸ¡å€ãæå€§åãã
ãçµéšã ã»è£œè¬äŒæ¥ã«ãããMA/MSLæ¥åçµéšïŒ3幎以äžïŒ ã»å»çåŸäºè ãšã®ç§åŠçãã£ã¹ã«ãã·ã§ã³çµéš ã»èšåºç ç©¶ã®äŒç»ãç«æ¡ãæšé²çµéš ã»è«æäœæãŸãã¯åŠäŒçºè¡šçµéš ãç¥èã ã»èšåºç ç©¶æ³ãå«çæéçã®é¢é£æ³èŠã«é¢ããåºç€ç¥è ã人ç©åã ã»å»çããŒãºãèµ·ç¹ã«äž»äœçã«èª²é¡ãç¹å®ãã解決ã«åããŠè¡åã§ããæ¹ ã»ç€Ÿå å€ã®é¢ä¿è ãšååããªããææåµåºã§ããæ¹ ã»å°æ¥ãã¡ãã£ã«ã«ã¢ãã§ã¢ãŒãºãªãŒããšããŠæé·ããææ¬²ãæããæ¹
粟ç¥ç¥çµé åããã³ããé åãéç¹çŸæ£é åãšããå»è¬åãåçã»çްèå»è¬çã«ãã倿§ãªã¢ãããŒãã§äººã ã®å¥åº·ã§è±ããªç掻ã«è²¢ç®ãç®çãšããŠããäŒæ¥ã åµè¬ç ç©¶å«ããã¡ãŒãäºæ¥åºç€ãæã€åœå ãšæâŒ€åžå Žã§ããç±³åœã«éç¹ã眮ãäºæ¥å±éããŠããã
380~430äž
ãæ¥åå å®¹ã æ°èŠåèšæ¡ä»¶ã®ç«ã¡äžãã«äŒŽãåéã§ããã¹ã¿ãŒãã¡ã³ããŒãšããŠåç»ã§ããåžå°æ§ã®é«ãããžã·ã§ã³ãšãªããŸãã å€è³è£œè¬ã¡ãŒã«ãŒã®çªå£æ åœãšããŠãæ°ãã«ç«ã¡äžããããŒã ã®ãªãŒããã³ã°ã¡ã³ããŒãåéããŸãã æ¬ããžã·ã§ã³ã§ã¯ãé»è©±ãäžå¿ã«åšå® å»çæ©åšïŒããã©ã€ã¶ãŒïŒã®äœ¿ç𿹿³ã®èª¬æãæäœæå°ãè¡ããŸããå šåœã®æ£è æ§ããå®¶æãå»çæ©é¢ããã®ãåãåããã«å¯Ÿå¿ããå®å¿ããŠæ²»çãç¶ç¶ã§ãããããµããŒããã圹å²ã§ãã 1æ¥ã®å¯Ÿå¿ä»¶æ°ã¯7ïœ10ä»¶çšåºŠãæ³å®ããŠãããäžä»¶äžä»¶ã«äžå¯§ã«åãåããªããæ¯æŽã§ããç°å¢ã§ãã ãŸãããªãŒããã³ã°ã¡ã³ããŒãšããŠã®åéã®ãããæ¢åã®äººéé¢ä¿ãæ £ç¿ã«ãšããããããšãªããã¡ã³ããŒå šå¡ã§ååããªããããŒã ãã€ããäžããŠãããç°å¢ã§ããç«å Žãå ¥ç€Ÿå¹Žæ¬¡ã«é¢ä¿ãªãæèŠãçºä¿¡ããããã颚éãã®è¯ãçµç¹ã¥ããã«æºãããŸãã æ¬ãããžã§ã¯ãã¯ç«ã¡äžããã§ãŒãºã®ãããæ¥åã«æ £ããåŸã¯éå¶äœå¶ã®æŽåãæ¥åæ¹åã«ãé¢ããããšãå¯èœã§ããæ±ºããããæ¥åãæ åœããã ãã§ã¯ãªããæ°ããããŒã ãä»çµã¿ã¥ããã«æºãããããšãããã®ããžã·ã§ã³ãªãã§ã¯ã®é åã§ãã æ¥åããã¥ã¢ã«ããã¬ããžã¯æŽåãããŠããã補åç¥èãå¿å¯Ÿæ¹æ³ãåŠã³ãªããå®å¿ããŠæ¥åã«åãçµããŸããæ®æ¥ãæ5æéçšåºŠãšå°ãªããã¯ãŒã¯ã©ã€ããã©ã³ã¹ã倧åã«ããªããåããç°å¢ã§ãã æ°èŠãããžã§ã¯ãã®æé·ãæ¯ããªãããæ£è æ§ãžã®è²¢ç®ãšèªèº«ã®ãã£ãªã¢åœ¢æã®äž¡æ¹ãå®çŸã§ããåžå°ãªããžã·ã§ã³ã§ãã ãäž»ãªæ¥åå 容ã ã»åšå® å»çæ©åšïŒããã©ã€ã¶ãŒïŒã®æäœèª¬æ ã»æ£è æ§ããå®¶ææ§ãå»çæ©é¢ããã®åãåããå¯Ÿå¿ ã»å¿å¯Ÿå 容ã®èšé²ã»å ±å ããã®ä»æ¥åã â PSPïŒPatient Support ProgramïŒæ£è ãµããŒãããã°ã©ã ïŒ é»è©±ã»ã¡ãŒã«ã»SMSãªã©ã掻çšããæ£è æ§ã®æè¬ç¶ç¶ãæ²»çç¶ç¶ãæ¯æŽããŸããæ£è æ§äžäººã²ãšãã«å¯ãæ·»ããªãããæ²»çç°å¢ã®åäžã«è²¢ç®ã§ããæ¥åã§ã â»æ¥åã®éœåã«ãã倿ŽãåœããããšããããŸãã
ãå¿ èŠãªèœåãçµéšã ã»æ£çè·åž«è³æ Œ ïŒåŠæŽäžå ã»ç æ£çµéšïŒåå1幎以äžïŒ ã»ã³ãã¥ãã±ãŒã·ã§ã³èœåïŒåŸèŽåãæèåã察話åïŒã®ããæ¹ ã»æããååãã«æ¥åã«åãçµããæ¹ ã»ååŒ·ææ¬²ãé«ãæ¹ ã»ç°¡åãªOAæäœèœå
ãDIãµãŒãã¹ ïŒ ã³ã³ã¿ã¯ãã»ã³ã¿ãŒãµãŒãã¹ãããBPOãµãŒãã¹ãããå»çæ©åšãµããŒããµãŒãã¹ããããã«ããã£ãã«ããã¢ãŒã·ã§ã³ãµãŒãã¹ããããã«ã¹ã±ã¢ãµãŒãã¹ãã®5ã€ã®åºè»žãµãŒãã¹ã«ãããŠã åžžã«ã客æ§ã®ããŒãºã«ãå¿ãã§ãããœãªã¥ãŒã·ã§ã³ãéçºã»æäŸããŠããäŒæ¥ã 30瀟è¿ãããã°ã«ãŒãäŒç€Ÿã§ãããã3ã®èŠæš¡ãèªããäžæ žçãªååšã®äŒç€Ÿã§ãã åŸæ¥å¡ã®å€ãã¯æè³æ Œè ïŒè¬å€åž«ãçè·åž«ãMRãç®¡çæ é€å£«çïŒã§ãã
790~1200äž
[Overview of Business and Organizational Structure] The AI Drug Development Division at NEC is advancing new drug discovery. We use NECâs advanced AI technologies. We work with top pharmaceutical companies to speed up development. Our headquarters is in Japan. We also run global clinical trials with NEC Laboratories Europe, NEC Laboratories America, and our subsidiaries in the Netherlands, Norway, and Germany. We seek life sciences expertise at the level of leading pharmaceutical companies. Our Translational Research team includes two members at headquarters and six overseas. The team leads R&D, runs validation experiments, and prepares proposals for pharmaceutical companies. We also handle business development. [Job description] Lead the development and execution of clinical research plans for immunotherapy in the fields of cancer, infectious diseases, and autoimmune diseases. Evaluate the biological validity and clinical applicability of insights derived from AI predictions, and when necessary, design and conduct validation experiments to advance the research. Analyze data and report findings to internal and external stakeholders. Prepare clear business communication materials?including scientific overviews, executive summaries, data visualizations, and technical documents?to support business development. Participate in technical due diligence of external technologies. [Key selling points of the position] Appeal and Rewards of This Position This position offers the opportunity to work at the intersection of AI and life sciences. You will use NECâs cutting-edge AI technology to support innovation in drug discovery. You can be involved in all stages, from early research to practical application. This hands-on work will help you gain a broad range of expertise. It is rewarding to know that your research may directly contribute to society in the future.
For positions ranging from Chief to Professional ãMUSTã ã»Ph.D. in fields such as immunology, virology, or oncology ã»at least 2 year experience in pharma or biotech in a matrixed international environements ã»Language: Japanese and English (both at business level or higher) ãWANTã Knowledge and experience in bioinformatics Hands-on experience with cell and animal experiments Background in pïœroteomics or mass spectrometry Familiarity with regulatory processes in drug development Experience studying or working abroad, or a TOEIC score of 800 or above
-
幎åéå ¬é
ã»å»çããã³æ²»çé åã®å°éå®¶ãæ²»éšè²¬ä»»å»åž«ããã®ä»ã¹ããŒã¯ãã«ããŒãšã®é¢ä¿æ§ç¯ããã³ç¶æ ã»æ¥çèŠå¶ãã³ã³ãã©ã€ã¢ã³ã¹ãéµå®ããäžã§ã®ãç§åŠçã»èšåºçåãåãããžã®å¯Ÿå¿ ã»å»çåŸäºè ãä¿éºæ¯æè ãç ç©¶è ã«å¯ŸããçŸæ£ç®¡çããã³æ²»çé åã«é¢ããæè²æŽ»å ã»åŠäŒãžã®åå ãéãããç§åŠã»èšåºããã³ç«¶åæ å ±ã®åéã»ç€Ÿå å ±æ ã»æ²»éšè²¬ä»»å»åž«ããã³ç€Ÿå ã¡ãã£ã«ã«éšéãšé£æºããå»åž«äž»å°ç ç©¶ïŒIISïŒã®æ¯æŽ ã»ãã¬ãŒã³ããŒã·ã§ã³ãè«æçãéããèšåºããŒã¿ã®äœæã»çºä¿¡æ¯æŽ ã»èšåºè©Šéšã«ãããæœèšç«ã¡äžãããã³è¢«éšè ç»é²æŽ»åã®ãµããŒã ã»ç€Ÿå ããªã·ãŒãæé ãããã³ã³ã³ãã©ã€ã¢ã³ã¹åºæºã®éµå®
â以äžã®ãããªãå¿åã»ãçµéšããæã¡ã®æ¹ãæè¿ããããŸãâ ã»ãªã³ã³ããžãŒé åã«åŒ·ãé¢å¿ããããç¹ã«èºãããåºåœ¢ããããŸãã¯è¡æ¶²è «çã«é¢ããå°éç¥èãæããŠããæ¹ ã»ãããªã¯ã¹åçµç¹ã«ãããŠä»éšéãšé£æºããªããæ¥åãæšé²ã§ããæ¹ããã€ã¢ã«ããã¢ããã³èšåºçŸå Žã«ãããé¢ä¿æ§ç¯ãåŸæãšããæ¹ ã»é«ãã³ãã¥ãã±ãŒã·ã§ã³èœåãæããæ¥æ¬èªããã³è±èªã§åæ»ãªæ¥åéè¡ãå¯èœãªæ¹ ã»å ç«è «çåŠããã³èšåºè©Šéšã«é¢ããå®åçµéšãæããã³ã³ãã©ã€ã¢ã³ã¹æèã®é«ãæ¹ ã»ã¹ããŒã¯ãã«ããŒãšã®é¢è«ãåŠäŒåå ã®ããã30ïœ50ïŒ çšåºŠã®åºåŒµãå¯èœãªæ¹ â以äžã®ããããã®ãçµéšã»è³æ Œããæã¡ã®æ¹ãæ³å®ããŠããŸãâ ã»å士å·ïŒPhDïŒãè¬åŠå士ïŒPharmDïŒããŸãã¯å»åŠå士ïŒMDïŒããæã¡ã®æ¹ïŒå°å¯ïŒ â»ä¿®å£«å·ããæã¡ã§ããªã³ã³ããžãŒé åã§è±å¯ãªå®åçµéšããæã¡ã®æ¹ãæ€èšå¯èœ ã»è£œè¬äŒæ¥ãŸãã¯èšåºçŸå Žã«ãããŠãDIïŒå»è¬åæ å ±ïŒæ¥åãçŸæ£ç®¡çããã°ã©ã çã«6幎以äžåŸäºãããçµéš ã»èºãããåºåœ¢ããããŸãã¯è¡æ¶²è «çé åã«ãããå°éæ§ãæããŠããæ¹ ã»å ç«è «çåŠïŒImmuno-OncologyïŒã®ãçµéšããæã¡ã§ããã°å°å¯
-
幎åéå ¬é
CVMé åã«ãããææ°æ å ±ãUnmet Medical Needsçã®æ å ±ãåéã»åæããããšã§ãMedical GAPãç¹å®ããæ£è ããã«è²¢ç®ããããã®MedicalæŠç¥ãèšç»ã»å®è¡ãã
æ±ããçµéšïŒ ã»ç ç©¶ããã³ã¡ãã£ã«ã«æŽ»åãèšç»ãå®è¡ããçµéš ã»æŠç¥ãç«æ¡ããããŒã ããªãŒãããçµéš ã»ïŒããã°å°å¯ïŒè£œè¬äŒç€Ÿã§ã®CVMé åïŒæè¥æºè¬ïŒæ åœçµéš ã»æ¬ç€ŸããŒã±ããããã¯ããããžã£ãŒãå¯ æ±ããã¹ãã«ã»ç¥èã»èœå ã»CVMé åã«ãããé«ãå°éæ§ãæããææ°ã®æ å ±ãæŽæ°ãç¶ããããããš ã»ç§åŠçããŒã¿ããšããã³ã¹ã«åºã¥ããè«çæ§ç¯å ã»åœå å€ã¹ã¿ãããšè¯å¥œãªã³ãã¥ãã±ãŒã·ã§ã³ãå¯èœã§ããããš æ±ããè¡åç¹æ§ïŒ ã»é«ãèŠåº§ãæã¡äžé·æçãªæŠç¥ãæ§ç¯ãããããåºã«è¡åã§ãã ã»å°é£ãªèª²é¡ã«å¯ŸããŠãé¢ä¿è ãå·»ã蟌ã¿ãªããæåã®è§£æ±ºçãå°ãåºãããšãã ã»é«ãå«ç芳ãæã¡ïŒåžžã«èª å®ãªè¡åã§ãé¡§å®¢ã®æåŸ ã«å¿ããããšãã§ãã æ±ããè³æ ŒïŒ TOEIC 730ç¹ä»¥äž ãŸãã¯åçã®è±èªã§ã®ã³ãã¥ãã±ãŒã·ã§ã³å
å»ççšå»è¬åã®ç ç©¶éçºã補é 販売ããã³èŒžåºå ¥
950~1200äž
CVMé åã«ãããææ°æ å ±ãUnmet Medical Needsçã®æ å ±ãåéã»åæããããšã§ãMedical GAPãç¹å®ããæ£è ããã«è²¢ç®ããããã®MedicalæŠç¥ãèšç»ã»å®è¡ãã
æ±ããçµéšïŒ ã»ç ç©¶ããã³ã¡ãã£ã«ã«æŽ»åãèšç»ãå®è¡ããçµéš ã»æŠç¥ãç«æ¡ããããŒã ããªãŒãããçµéš ã»ïŒããã°å°å¯ïŒè£œè¬äŒç€Ÿã§ã®CVMé åïŒæè¥æºè¬ïŒæ åœçµéš ã»æ¬ç€ŸããŒã±ããããã¯ããããžã£ãŒãå¯ æ±ããã¹ãã«ã»ç¥èã»èœå ã»CVMé åã«ãããé«ãå°éæ§ãæããææ°ã®æ å ±ãæŽæ°ãç¶ããããããš ã»ç§åŠçããŒã¿ããšããã³ã¹ã«åºã¥ããè«çæ§ç¯å ã»åœå å€ã¹ã¿ãããšè¯å¥œãªã³ãã¥ãã±ãŒã·ã§ã³ãå¯èœã§ããããš æ±ããè¡åç¹æ§ïŒ ã»é«ãèŠåº§ãæã¡äžé·æçãªæŠç¥ãæ§ç¯ãããããåºã«è¡åã§ãã ã»å°é£ãªèª²é¡ã«å¯ŸããŠãé¢ä¿è ãå·»ã蟌ã¿ãªããæåã®è§£æ±ºçãå°ãåºãããšãã ã»é«ãå«ç芳ãæã¡ïŒåžžã«èª å®ãªè¡åã§ãé¡§å®¢ã®æåŸ ã«å¿ããããšãã§ãã æ±ããè³æ ŒïŒ TOEIC 730ç¹ä»¥äž ãŸãã¯åçã®è±èªã§ã®ã³ãã¥ãã±ãŒã·ã§ã³å
-